These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35675968)

  • 1. The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care.
    Janke MJ; Santiago S; Straubhar AM; Uppal S
    Int J Gynecol Cancer; 2022 Jul; 32(7):913-917. PubMed ID: 35675968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study.
    Feinberg J; Carthew K; Webster E; Chang K; McNeil N; Chi DS; Long Roche K; Gardner G; Zivanovic O; Sonoda Y
    Int J Gynecol Cancer; 2022 Feb; 32(2):159-164. PubMed ID: 34969828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
    Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
    Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of regular physical examination in the detection of ovarian cancer recurrence.
    Chan KK; Tam KF; Tse KY; Ngan HY
    Gynecol Oncol; 2008 Aug; 110(2):158-61. PubMed ID: 18544459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
    Armstrong A; Otvos B; Singh S; Debernardo R
    Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.
    Dao MD; Alwan LM; Gray HJ; Tamimi HK; Goff BA; Liao JB
    Gynecol Oncol; 2013 Aug; 130(2):295-9. PubMed ID: 23632207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
    Guo N; Peng Z
    J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.
    Krell D; Said Battistino F; Benafif S; Ganegoda L; Hall M; Rustin GJS
    Int J Gynecol Cancer; 2017 Jul; 27(6):1118-1122. PubMed ID: 28333841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients.
    Fehm T; Heller F; Krämer S; Jäger W; Gebauer G
    Anticancer Res; 2005; 25(3A):1551-4. PubMed ID: 16033059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
    Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
    Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
    Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
    Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.
    Alexander VM; Gordon AN; Howard DH; Khanna N
    Int J Gynecol Cancer; 2017 Sep; 27(7):1333-1342. PubMed ID: 28692633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
    Yang ZJ; Zhao BB; Li L
    J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Goto T; Takano M; Watanabe A; Miyamoto M; Kato M; Hirata J; Sasa H; Furuya K
    Int J Gynecol Cancer; 2011 Feb; 21(2):263-8. PubMed ID: 21270609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
    Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
    Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
    Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain.
    Wang N; Li C; Yang Y; Guan Y; Wang F; Wang Y; Zhao W
    World Neurosurg; 2021 May; 149():502-510. PubMed ID: 33326856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
    J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.